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Abstract
Aim: The aim of this study was to examine the role of hereditary thrombophilia in the development of fetal
growth retardation (FGR) in the population of Central Russia.
Methods: The case–control study sample included 497 women in the third trimester of pregnancy recruited
during 2009–2013. The participants were enrolled into two groups: patients with FGR (n = 250) and controls
without FGR (n = 247). The participants were genotyped for four genetic markers of hereditary thrombophilia:
factor V Leiden (G > A FV, rs6025), prothrombin (G > A FII, rs1799963), factor VII (G > A FVII, rs6046), and
ﬁbrinogen (G > A FI, rs1800790).
Results: The genetic factors for an increased risk of FGR were allele G of rs6046 (odds ratio [OR] = 2.34) and
genotype GG of rs6046 (OR = 2.64), whereas genotype GA of rs6046 had the protective value (OR = 0.42). A
combination of alleles G of rs1799963, A of rs6046, and G of rs1800790 (OR = 0.31) reduces the risk of FGR.
Conclusion: Polymorphism rs6046 of the FVII gene is associated with the development of FGR.
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Introduction
Thrombophilia is the pathological condition of the body
characterized by an increased risk of intravascular
thrombosis due to inherited or acquired disorders of
hemostasis.1,2 Women with acquired or inherited
thrombophilia are at increased risk for thrombotic and
gestational complications.3–10 At least 50% of thrombotic
complications of pregnancy are associated with
thrombophilia.6,11 Thrombophilia is the most important
risk factor for several obstetric complications, for
example, fetal loss syndrome (39.1%), severe pre-
eclampsia (18.2%), chorionic detachment (11.5%),
thrombosis during pregnancy and the post-partum
period, and placental abruption (13.63%).12 The most
signiﬁcant markers for the development of gestational
complications of congenital thrombophilia are mutation
Leiden 1691G > A FV, prothrombin 20210G > A FII,
plasminogen activator inhibitor 4G > 5G PAI-1, 677S >
T MTHFR, deﬁciency of protein S, protein C,
antithrombin III, and others.9,10,12 Over 52% of women
with obstetric complications have thrombophilic gene
defects.7
Factor V Leiden thrombophilia is caused by a
substitution of G by A at position 1691 of the gene and,
respectively, replacement of arginine by glutamine at
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position 506 of the protein.13,14 This results in resistance
of the factor V Leiden variant to inactivation by the
activated protein C and thus promotes clotting.14,15 The
polymorphism inheritance follows the autosomal
dominant principle. About 4–7% of European
Caucasians are heterozygous for this mutation.16
The 20210G > A FII variant of prothrombin is located
in the 30-untranslated region of the gene. Although this
substitution does not result in an amino acid change, it
was associated with the up to 1.5–2 times elevated level
of the normal prothrombin.17 The elevated level of
prothrombin results in the higher level of thrombin that
activates clotting through the positive feedback
mechanism. Such an activation of the clotting
mechanism confers an increased risk of thrombosis.17
Inheritance of the polymorphism follows the autosomal
dominant principle. The frequency of heterozygotes in
Caucasians is about 2–5%.1,18,19
The –455G > A FI polymorphism is located in the
promoter of the ﬁbrinogen β-chain. It has been
associated with the increased risk of thrombosis.20 The
prevalence of this polymorphism in European
populations is 5–10%.1
Mutation 10976G > A FVII results in a replacement of
Arg by Gln in position 353 of the respective protein. This
mutation was associated with the low concentration of
the FVII protein in blood plasma.21 Heterozygotes
10976G > A FVII have 25% lower concentration of the
protein, homozygotes 10976АA – 50% lower as
compared to the most common genotype 10976GG. In
addition, homozygotes 10976GG are at higher risk for
cardiovascular health problems and complications at
pregnancy.21,22 The frequency in the European
population is 10–20%.23,24
The available data about the role of the genetic
markers for inherited thrombophilia in the fetal growth
retardation are inconsistent. Several studies have
reported a signiﬁcant association of the 1691G > A FV
with FGR in Caucasian females from: Canada (odds
ratio [OR] = 2.7; 95% conﬁdence interval [CI], 1.3–5.5),5
the USA (OR = 1.23; 95%CI, 1.04–1.44),25 and France
(ОR = 2.58; 95%CI, 0.83–8.04).26 The signiﬁcant
association of the 20210G > A FII polymorphism with
FGR was determined in Caucasian women from
Canada (OR = 2.5; 95%CI, 1.3–5.0)5 and France (OR =
2.03; 95%CI, 0.51–8.01).26 The contradictory data were
reported by Franchi et al.,4 who did not ﬁnd signiﬁcant
associations of the 1691G > A FV, 20210G > A FII, and
677С/T MTHFR polymorphisms with FGR. We have
not found any data about the association of the –455G
> A FI and 10976G > A FVII polymorphisms with FGR.
Methods
Study population
In total, 497 unrelated pregnant women in the third
trimester of pregnancy were recruited for the study
during 2009–2013. All participants signed an informed
consent before entering the study. The clinical and
laboratory examination of the participants was
conducted in the perinatal center of the Saint Joasaph
Belgorod Regional Clinical Hospital. The following
inclusion criteria were used to check eligibility of the
participants: singleton pregnancy and Russian ethnicity.
Patients having congenital malformations of internal
genitals, uterine ﬁbroids, anomalies of placental location,
isosensitization of Rh factor or ABO, or genetic 
diseases Q5 were excluded from the study.
Two hundred and ﬁfty participants were diagnosed
with the syndrome of intrauterine growth retardation
of varying severity. The diagnosis of the syndrome was
based on clinical data, ultrasound fetometry (TOSHIBA
XARIO SSA-660A) and parameters of growth and
weight after the birth. Based on the differences between
the fetometric data and nomograms, three degrees of
FGR were classiﬁed: ﬁrst degree corresponded to the
reduction of the estimated gestational ages from the
standard ones by 2 weeks; second degree – by 3–4
weeks; and third degree – by more than 4 weeks.27
The controls were 247 women without the syndrome
of intrauterine growth retardation.
DNA isolation and genotyping assay
Each participant donated 6 mL of blood drawn from a
cubital vein. Genomic DNA was isolated according to
Miller et al.28 The participants were genotyped for four
candidate genetic markers for hereditary thrombophilia:
Leiden mutation of coagulation factor V (G > A FV,
rs6025), prothrombin (G > A FII, rs1799963), factor VII
(G > A FVII, rs6046), and ﬁbrinogen (G/A FI, rs1800790).
The polymorphisms were genotyped using the
TaqMan real-time PCR assays with the standard primers
and probes (Syntol, Russia).29,30 The data were
processed using BioRad CFX Manager 3.1 (Bio-Rad
Laboratories, Inc.).
Statistical analysis
The obtained genotypes were checked for their
correspondence to the Hardy–Weinberg distribution
(HWE) using the χ2-test. Association of the
polymorphisms with FGR was estimated by analyzing
2 × 2 contingency tables with the χ2-test and Yates’
correction for continuity. The risk was estimated using
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ORwith 95%CI. Association of the polymorphisms with
FGR was analyzed using logistic regression with
adjustment for cofactors (somatic and gynecological
pathologies). The analyses were performed using
STATISTICA 6.0 (StatSoft).
Possible allele combinations of the studied
polymorphisms and their signiﬁcance for FGR were
analyzed using the Markov chain Monte Carlo and
Bayes nonparametric statistics as implemented in
APSampler (http://sources.redhat.com/cygwin/).31
Bonferroni correction was applied to adjust for multiple
comparisons.
Results
The summary characteristics of the case and 
control groups are given in Table 1.
First-degree FGR was diagnosed in 133 patients
(53.20%), second-degree in 96 patients (38.40%), and
third-degree in 21 patients (8.40%).
The FGR patients had a 1.8-fold higher rate of
spontaneous abortion predominantly in the ﬁrst
trimester of pregnancy than the controls.
All genotypes but one showed no deviation from the
HWE. The only case of the deviation was observed in
the case group at the G/A FV rs6025 locus (χ2 = 6.58; P
< 0.05). This can be explained by the presence of a single
homozygote АA FV rs6025. After this genotype was
removed, no deviation was observed (χ2 = 0.09; P >
0.05).
FGR patients had higher frequency of allele G FVII
rs6046 (88.72%) and genotype GG FVII rs6046 (77.87%),
and lower frequency of genotype GA FVII rs6046
(21.70%) as compared to the controls (77.07%, 57.07%,
and 40.00%, respectively; Table 2).
The frequency of a combination of alleles G FII
rs1799963, A FVII rs6046, and G FI rs1800790 was
approximately half (19.8%) that in the case group as
compared to the controls (44.5%) (ОR = 0.31; 95%CI,
0.20–0.48; PFischer’s < 0.0001, PBonferroni < 0.0001).
The results of the logistic regression analysis showed
that polymorphism G > A FVII rs6046 was signiﬁcantly
associated with a risk for FGR both individually and
after adjustment for the cofactors, which were present
in the patients and absent in the controls (i.e.,
miscarriage, essential hypertension; Table 3).
Discussion
The present study shows the association of genetic
markers of hereditary thrombophilia G > A FVII rs6046
with the development of FGR in the population of
Table 1 Physical characteristics and various medical pathologies in the study participants
FRG patients, n (%) Controls, n (%) P
N 250 247 —
Age, years (min–max) 26.78 ± 4.81 (16.0–45.0) 26.20 ± 5.01 (19.0–41.0) >0.05
BMI, kg/m2 23.37 ± 4.31 23.90 ± 3.96 >0.05
Somatic pathologies
Essential hypertension 50 (20.00) 29 (11.74) 0.02
Chronic pyelonephritis 63 (25.20) 55 (22.27) 0.51
Obesity 23 (9.20) 22 (8.91) 1.00
Varicose veins 13 (5.20) 10 (4.05) 0.69
Venous thromboembolism at pregnancy 4 (1.60) 1 (0.41) 0.38
Chronic gastroduodenitis 26 (10.40) 22 (8.89) 0.68
History of cerebrovascular disease 2 (0.80) 0 0.50
Gynecological pathologies
History of medical abortion 80 (32.00) 65 (26.32) 0.20
History of infertility 5 (2.00) 8 (3.24) 0.56
History of miscarriage (total) 46 (18.40) 25 (10.12) 0.01
Miscarriage in ﬁrst trimester 36 (14.40) 20 (8.10) 0.04
Pregnancy loss in ﬁrst trimester 12 (4.80) 12 (4.86) 1.00
Ectopic pregnancy 10 (4.00) 15 (6.07) 0.39
History of disorders of the menstrual cycle 20 (8.00) 14 (5.67) 0.39
History of pelvic inﬂammatory disease 58 (23.20) 59 (23.89) 0.94
Intrauterine infection during pregnancy 83 (33.20) 80 (32.39) 0.68
Pre-eclampsia 55 (22.00) 68 (27.53) 0.19
Antenatal intrauterine fetal death 4 (1.60) 0 0.14
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Central Russia. Genetic factors of an increased risk for
FGR are allele G FVII rs6046 and genotype GG FVII
rs6046, whereas allele A FVII rs6046 has a protective
value. The combination of alleles G FII, A FVII, and G
FI reduces the risk of FGR (OR = 0.31; 95%CI, 0.20–0.48).
The association of the rs6046 polymorphism of the
FVII gene with FGR remained signiﬁcant after
adjustment for cofactors (miscarriage and essential
hypertension). However, the signiﬁcance level was
lower (P = 0.04 vs P = 0.003–0.004 without the
adjustment). This may be due to the opposite effect of
this polymorphism and the cofactors: Allele A was
protective for FGR (OR = 0.43 for allele A [95%CI,
0.29–0.63] and 0.42 for genotype GA [95%CI,
0.27–0.64]), while essential hypertension and
miscarriage were 1.7–1.8-fold more common in the
FGR patients than in the controls, which was implicated
in a higher risk for FGR.32,33
The observed association of the G > A FVII rs6046
polymorphism with the development of FGR is
consistent with the available data on the physiological
role of this factor in the hemostatic system. According
to modern concepts, coagulation factor VII
(proconvertin) is one of the key factors in the coagulation
cascade and participates in the external way of the
activation of blood coagulation.22,34 The complex
consisting of tissue factor, the active form of the
Table 2 Frequencies of the studied SNP and respective genotypes in case and control samples
Polymorphism Studied groups Alleles, genotypes Frequency, % OR (95%CI) χ2 P
G > A FII rs1799963 Case G 98.40 0.44 (0.09–1.83) 0.87 0.35
Control G 99.29
Case GG 96.80 0.44 (0.09–1.83) 0.88 0.35
Control GG 98.58
Case GA 3.20 2.29 (0.55–11.04) 0.88 0.35
Control GA 1.42
Case AA 0 — — —
Control AA 0 — — —
G > A FI rs1800790 Case G 79.20 1.18 (0.87–1.61) 1.04 0.31
Control G 76.32 — — —
Case GG 64.40 1.27 (0.87–1.86) 1.47 0.23
Control GG 58.70 — — —
Case GA 29.60 0.77 (0.52–1.15) 1.55 0.21
Control GA 35.22 — — —
Case AA 6.00 0.99 (0.46–2.19) 0.001 1.00
Control AA 6.07 — —
G > A FV rs6025 Case G 97.77 0.59 (0.19–1.74) 0.63 0.43
Control G 98.67
Case GG 95.95 0.65 (0.21–1.97) 0.34 0.56
Control GG 97.35 — — —
Case GA 3.64 1.32 (0.44–4.46) 0.12 0.73
Control GA 2.65 — — —
Case AA 0.40 — — —
Control AA 0 — — —
G > A FVII rs6046 Case G 88.72 2.34 (1.60–3.44) 20.53 0.0005
Control. G 77.07 — — —
Case GG 77.87 2.64 (1.71–4.09) 20.88 0.0005
Control GG 57.07 — — —
Case GA 21.70 0.42 (0.27–0.64) 16.52 0.0006
Control GA 40.00 — — —
Case AA 0.43 0.21 (0.01–2.03) 1.13 0.29
Control AA 2.93 — — —
Table 3 Results of the univariate regression analysis
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coagulation factor VIIa, and calcium ions promotes
formation of the active forms of factor X (Xa), which is
a common way of initiating the coagulation cascade. In
addition, the complex is able to activate factor IX (IXa)
of the intrinsic pathway of blood coagulation that
further strengthens the process of blood coagulation.22,34
The Factor VII gene is located on the long arm of
chromosome 13 (13q34). The GA heterozygotes and
AA homozygotes of FVII rs6046 have, respectively,
approximately 25% and 50% lower blood concentration
of Factor VII as compared with the wild-type GG
heterozygotes.21,35 The elevated levels of this factor can
result in a hypercoagulable state and thrombotic
complications,21,22,33 causing the development of
placental insufﬁciency with the formation of FGR.
We have not found any signiﬁcant associations of
markers G > A FI rs1800790, G > A FII rs1799963, or G
>A FVrs6025with a risk for FGR. This is in concordance
with some previous studies on American and European
Caucasians,1,4 whereas it contradicts other studies5,25,26
(Table 4).
The inconsistency in the results may be related to the
respective differences in the ethnic and genetic
backgrounds of the studied populations. Population
genetic stratiﬁcation was shown to have a signiﬁcant
effect on the prevalence and expression of quantitative
traits in various populations.36
The results of the study show that the polymorphism
G > A FVII rs6046 alone, as well as in combination with
other markers of hereditary thrombophilia, G > A FI
rs1800790 and G > A FII rs1799963, is associated with
the development of FGR. These results extend the
existing ideas about the role of hereditary thrombophilia
in the pathogenesis of placental insufﬁciency syndrome
and fetal growth retardation.
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